PHASE-II STUDY OF VINORELBINE IN HEAVILY PREVIOUSLY TREATED SMALL-CELL LUNG-CANCER

Citation
K. Furuse et al., PHASE-II STUDY OF VINORELBINE IN HEAVILY PREVIOUSLY TREATED SMALL-CELL LUNG-CANCER, Oncology, 53(2), 1996, pp. 169-172
Citations number
18
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
ISSN journal
0030-2414
Volume
53
Issue
2
Year of publication
1996
Pages
169 - 172
Database
ISI
SICI code
0030-2414(1996)53:2<169:PSOVIH>2.0.ZU;2-H
Abstract
Twenty-four previously treated patients with refractory or relapsed sm all cell lung cancer (SCLC) were entered into a prospective, multicent er phase II study. All 24 patients had been pretreated with some form of cisplatin-based chemotherapy. The median time of chemotherapy was 4 .2 months (range 1.4-9.4 months). Patients were treated with a dose of 25 mg/m(2) of vinorelbine weekly. Twenty-four patients were eligible for response and for toxicity. Partial response was observed in 3 out of 24 eligible patients (12.5%; 95% confidence interval, 2.7-32.4%). A ll 3 patients who responded had previous chemotherapy including vincri stine. The most common toxicity was leukopenia (91.7%, 66.7% in WHO 3- 4 grade) and anemia (70.8%, 20.8% in WHO 3 grade). Nonhematological to xicities were moderate and mild. These results support a two-stage seq uential study design of previously untreated patients for further phas e II study in SCLC.